Uncategorised

Sanofi and GSK partner to develop Covid-19 vaccine

April 14, 2020

Sanofi and GlaxoSmithKline (GSK) have signed a letter of intent for a partnership focused on developing an adjuvanted vaccine for Covid-19.

While Sanofi and GSK are also working separately to enable vaccines for the viral infection, the latest alliance is intended to combine their respective technologies.

Read the full article here

More Relevant

Data Insights

Influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine by Sinovac Biotech for Seasonal Influenza: Likelihood of Approval

Data Insights

Vaccine for Oncology by CAS-Lamvac Biotech for Liver Cancer: Likelihood of Approval

Data Insights

Vaccine for Oncology by CAS-Lamvac Biotech for Thyroid Cancer: Likelihood of Approval

Sign up to the newsletter: In Brief

Your corporate email address *

First name *

Last name *

Company name *

Job title *

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

Go deeper with GlobalData

LOA and PTSR Model - typhoid (bivalent) vaccine

LOA and PTSR Model - COVID/Influenza Combination Vaccine

Premium Insights

LOA and PTSR Model - typhoid (bivalent) vaccine

LOA and PTSR Model - COVID/Influenza Combination Vaccine

Premium Insights

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief